Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This is a Phase 1 trial focused on safety in people who've had a STEMI with cardiogenic shock — what does that mean for how much is known about whether FAP iCDC actually helps patients in my situation, versus just testing whether it's safe to give?
2. 2Since the trial isn't recruiting yet, how long might it realistically be before it opens, and should we be making treatment decisions now rather than waiting for a study that may not be available soon?
3. 3The main things being measured are dose-limiting toxicity and treatment-emergent adverse events — given how critical cardiogenic shock already is, what kinds of serious side effects would I need to be prepared for if I were to consider a Phase 1 cell therapy on top of that?
4. 4Are there standard-of-care treatments for post-STEMI cardiogenic shock — like mechanical circulatory support or existing medications — that I should be pursuing first, and would enrolling in this trial affect access to those?
5. 5What does 'FAP iCDC' actually do to the heart, and is my care team familiar enough with this type of cell therapy to help me weigh whether the experimental risk makes sense given how sick I already am?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.